Inhibition of HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-CoA) by statins is an established treatment for the prevention of cardiovascular disease, and has recently been found to improve exercise capacity in chronic obstructive pulmonary disease patients with pulmonary hypertension 25. This evidence concerns the gene HMGCR and chronic obstructive pulmonary disease.